Korro Bio (NASDAQ:KRRO) Stock Price Down 4%

Shares of Korro Bio, Inc. (NASDAQ:KRRO) dropped 4% during trading on Thursday . The stock traded as low as $66.06 and last traded at $66.52. Approximately 14,025 shares changed hands during trading, a decline of 49% from the average daily volume of 27,381 shares. The stock had previously closed at $69.30.

Analyst Ratings Changes

KRRO has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Korro Bio from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Korro Bio in a report on Wednesday, March 27th. Royal Bank of Canada boosted their price target on shares of Korro Bio from $70.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, March 27th. Finally, BMO Capital Markets restated an “outperform” rating and set a $120.00 price target on shares of Korro Bio in a report on Tuesday, March 26th.

Korro Bio Trading Down 0.1 %

The company’s fifty day moving average is $63.69.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KRRO. Atlas Venture Life Science Advisors LLC acquired a new position in Korro Bio in the 4th quarter valued at approximately $53,648,000. Eventide Asset Management LLC acquired a new position in Korro Bio in the 4th quarter valued at approximately $26,185,000. 72 Investment Holdings LLC acquired a new position in Korro Bio in the 4th quarter valued at approximately $13,269,000. Vanguard Group Inc. acquired a new position in Korro Bio in the 4th quarter valued at approximately $12,988,000. Finally, Point72 Asset Management L.P. acquired a new position in Korro Bio in the 4th quarter valued at approximately $12,741,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.